Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The study will test the effectiveness (rate of complete remissions, total remission rate and
duration of remission) and toxicity of the combined immuno/chemotherapy with subcutaneous
cladribine (LITAK®) plus anti-CD20* antibody rituximab in patients requiring treatment for
relapsed hairy cell leukaemia or hairy cell leukaemia variant independent of any previous
therapy.
CD20* = cluster of differentiation antigen 20